Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 9, 2013, Pages 3864-3872

  Bredella, Miriam A ^a   Gerweck, Anu V ^a   Lin, Eleanor ^a   LanD A , Melissa G ^a   Torriani, Martin ^a   Schoenfeld, David A ^a   Hemphill, Linda C ^a   Miller, Karen K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; GLUCOSE; HEMOGLOBIN A1C; HUMAN GROWTH HORMONE; LOW DENSITY LIPOPROTEIN; PLACEBO; SOMATOMEDIN C;

ABDOMINAL FAT; ABDOMINAL OBESITY; ADULT; ARTERIAL WALL THICKNESS; ARTHROPATHY; ARTICLE; BACKACHE; BODY COMPOSITION; CARDIOVASCULAR RISK; CELL FUNCTION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED HEADACHE; DUAL ENERGY X RAY ABSORPTIOMETRY; EDEMA; ENDOTHELIUM; FATTY LIVER; HUMAN; INTRAABDOMINAL FAT; JOINT DISCOMFORT; LIMB; MAJOR CLINICAL STUDY; MALE; MITOCHONDRION; MUSCLE MASS; MYALGIA; NOSE OBSTRUCTION; ORAL GLUCOSE TOLERANCE TEST; PARESTHESIA; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SUBCUTANEOUS FAT; THIGH; TRUNK; WEIGHT GAIN;

ABDOMINAL FAT; ADULT; BODY COMPOSITION; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; DOUBLE-BLIND METHOD; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MITOCHONDRIA; OBESITY, ABDOMINAL; TREATMENT OUTCOME;

EID: 84883688944     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2063     Document Type: Article

References (40)

1. Rexrode KM, Carey VJ, Hennekens CH, et al. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-1848.
2. Snijder MB, Visser M, Dekker JM, et al. Low subcutaneous thigh fat is a risk factor for unfavourable glucose and lipid levels, independently of high abdominal fat. The Health ABC Study. Diabetologia. 2005;48:301-308.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002; 346:1221-1231.
4. Miller KK, Biller BM, Lipman JG, Bradwin G, Rifai N, Klibanski A. Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk. J Clin Endocrinol Metab. 2005;90:768-774.
5. Pijl H, Langendonk JG, Burggraaf J, et al. Altered neuroregulation of GH secretion in viscerally obese premenopausal women. J Clin Endocrinol Metab. 2001;86:5509-5515.
6. Utz AL, Yamamoto A, Hemphill L, Miller KK. Growth hormone deficiency by growth hormone releasing hormone-Arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women. J Clin Endocrinol Metab. 2008;93:2507-2514.
7. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009; 30:152-177.
8. Rudling M, Angelin B. Loss of resistance to dietary cholesterol in the rat after hypophysectomy: importance of the presence of growth hormone for hepatic low density lipoprotein-receptor expression. Proc Natl Acad Sci U S A. 1993;90:8851-8855.
9. Bredella MA, Torriani M, Thomas BJ, et al. Peak growth hormone releasing hormone-Arginine-stimulated growth hormone is inversely associated with intramyocellular and intrahepatic lipid content in premenopausal women with obesity. J Clin Endocrinol Metab. 2009;94:3995-4002.
10. Short KR, Moller N, Bigelow ML, Coenen-Schimke J, Nair KS. Enhancement of muscle mitochondrial function by growth hormone. J Clin Endocrinol Metab. 2008;93:597-604.
11. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384-387.
12. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671.
13. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol. 2001;3:1009-1013.
14. Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A randomized, placebo-controlled trial. Ann Intern Med. 1996;125:883-890.
15. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab. 2008;93:2063-2071.
16. Bengtsson BA, Johannsson G. Effect of growth-hormone therapy on early atherosclerotic changes in GH-deficient adults. Lancet. 1999; 353:1898-1899.
17. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133:111-122.
18. Bredella MA, Lin E, Brick DJ, et al. Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo- controlled trial. Eur J Endocrinol. 2012;166:601-611.
19. Franco C, Brandberg J, Lönn L, Andersson B, Bengtsson BA, Johannsson G. Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12- month placebo-controlled trial. J Clin Endocrinol Metab. 2005;90: 1466-1474.
20. Johannsson G, Marin P, Lönn L, et al. Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure. J Clin Endocrinol Metab. 1997;82:727-734.
21. Pasarica M, Zachwieja JJ, Dejonge L, Redman S, Smith SR. Effect of growth hormone on body composition and visceral adiposity in middle-Aged men with visceral obesity. J Clin Endocrinol Metab. 2007;92:4265-4270.
22. Tomlinson JW, Crabtree N, Clark PM, et al. Low-dose growth hormone inhibits 11 beta-hydroxysteroid dehydrogenase type 1 but has no effect upon fat mass in patients with simple obesity. J Clin Endocrinol Metab. 2003;88:2113-2118.
23. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106: 3143-3421.
24. Han TS, van Leer EM, Seidell JC, Lean ME. Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. BMJ. 1995;311:1401-1405.
25. Bredella MA, Lin E, Gerweck AV, et al. Determinants of bone microarchitecture and mechanical properties in obese men. J Clin Endocrinol Metab. 2012;97:4115-4122.
26. Fleischman A, Kron M, Systrom DM, Hrovat M, Grinspoon SK. Mitochondrial function and insulin resistance in overweight and normal-weight children. J Clin Endocrinol Metab. 2009;94:4923-4930.
27. Hosseini Ghomi R, Bredella MA, Thomas BJ, Miller KK, Torriani M. Modular MR-compatible lower leg exercise device for wholebody scanners. Skeletal Radiol. 2011;40:1349-1354.
28. Meyerspeer M, Krssak M, Moser E. Relaxation times of 31P-metabolites in human calf muscle at 3 T. Magn Reson Med. 2003;49: 620-625.
29. Gomez JM, Espadero RM, Escobar-Jimenez F, et al. Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clin Endocrinol (Oxf). 2002;56:329-334.
30. Paffenbarger RS Jr, Blair SN, Lee IM, Hyde RT. Measurement of physical activity to assess health effects in free-living populations. Med Sci Sports Exerc. 1993;25:60-70.
31. Aaron DJ, Kriska AM, Dearwater SR, Cauley JA, Metz KF, LaPorte RE. Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. Am J Epidemiol. 1995;142:191-201.
32. Makimura H, FeldpauschMN,Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012;97:4769-4779.
33. Björntorp P. "Portal" adipose tissue as a generator of risk factors for cardiovascular disease and diabetes. Arteriosclerosis. 1990;10:493-496.
34. Poulain-Godefroy O, Lecoeur C, Pattou F, Frühbeck G, Froguel P. Inflammation is associated with a decrease of lipogenic factors in omental fat in women. Am J Physiol Regul Integr Comp Physiol. 2008;295:R1-R7.
35. Levene AP, Goldin RD. The epidemiology, pathogenesis and histopathology of fatty liver disease. Histopathology. 2012;61:141-152.
36. Fowelin J, Attvall S, Lager I, Bengtsson BA. Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism. 1993;42:1443-1447.
37. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87:2121-2127.
38. Krusenstjerna-Hafstrom T, Clasen BF, Moller N, et al. Growth hormone (GH)-induced insulin resistance is rapidly reversible: an experimental study in GH-deficient adults. J Clin Endocrinol Metab. 2011;96:2548-2557.
39. Schrauwen-Hinderling VB, KooiME,HesselinkMK,et al. Impaired in vivo mitochondrial function but similar intramyocellular lipid content in patients with type 2 diabetes mellitus and BMI-matched control subjects. Diabetologia. 2007;50:113-120.
40. FidlerMC,Sanchez M, Raether B, et al.Aone-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067-3077.